These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1794627)

  • 1. European project concerning the guidelines on medicinal products derived from human blood and plasma.
    Horaud F
    Dev Biol Stand; 1991; 75():237-40. PubMed ID: 1794627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Community requirements relating to drugs derived from human blood and plasma].
    Brunko P
    Ann Pharm Fr; 1994; 52(2):89-98. PubMed ID: 7944184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
    [No Abstract]   [Full Text] [Related]  

  • 4. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):159-64. PubMed ID: 1389112
    [No Abstract]   [Full Text] [Related]  

  • 6. The regulation of medicinal products derived from human blood or plasma in the European Community.
    Brunko P
    Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813
    [No Abstract]   [Full Text] [Related]  

  • 7. EEC legislation of medicinal products of biological origin.
    Brunko P; Sauer F
    Dev Biol Stand; 1991; 75():21-5. PubMed ID: 1794622
    [No Abstract]   [Full Text] [Related]  

  • 8. The EEC and the regulation of blood derivatives.
    Horaud F
    Dev Biol Stand; 1993; 81():273-6. PubMed ID: 8174814
    [No Abstract]   [Full Text] [Related]  

  • 9. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 11. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Viral safety: European and French directives].
    Rossi F; Legras JF
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S55-61. PubMed ID: 10896992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The harmonization of the regulation of blood products: a European perspective.
    Seitz R; Heiden M; Nübling CM; Unger G; Löwer J
    Vox Sang; 2008 May; 94(4):267-76. PubMed ID: 18179678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status of the GCP guidelines in Europe.
    Geussenhainer S
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):223-8. PubMed ID: 8361259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An industry perspective on plasma-derived products.
    von Hoegen I
    Dev Biol (Basel); 2004; 118():31-5. PubMed ID: 15645670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.